Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a phase IV, single-center, randomized, placebo-controlled pilot study that will
evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with
active otolaryngologic disease.